Lemtrada
Named-patient access overview. Lemtrada is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Lemtrada (alemtuzumab) is a humanised anti-CD52 monoclonal antibody developed by Sanofi-Genzyme. The US Food and Drug Administration approved Lemtrada in November 2014 for adults with relapsing forms of multiple sclerosis, generally reserved for patients who have had an inadequate response to two or more disease-modifying therapies given its risk profile. Dosing is intravenous in a pulsed schedule, with five consecutive daily infusions in the first course and three consecutive daily infusions in the second course twelve months later, plus optional additional courses based on clinical response. Treatment is administered in a hospital or specialised infusion centre under neurology supervision, with mandatory monthly laboratory monitoring and a long REMS-style monitoring period for autoimmune, infection, and malignancy risks.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Lemtrada
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Lemtrada is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Lemtrada in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Lemtrada
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Lemtrada if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Lemtrada for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Lemtrada through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Lemtrada. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Lemtrada through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Lemtrada to a patient?
Reserve Meds sources Lemtrada from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Lemtrada cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Lemtrada?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.